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ABSTRACT
Progressive multifocal leukoencephalopathy is a neurological infectious disease caused by the 
John Cunningham polyomavirus (JCV), an opportunistic agent with worldwide distribution. This 
disease is frequently seen in immunosuppresed patients and rarely associated with systemic lupus 
erythematosus. In the central nervous system PML demyelinating lesions occur in the supraten-
torial compartment. The authors describe a rare case of PML secondary to SLE treatment with 
atypical presentation restricted to the posterior fossa.
Keywords: PML; leukoencephalopathy; progressive multifocal posterior fossa; magnetic resonance; 
spectroscopy; diffusion weighted images.
INTRODUCTION
Progressive multifocal leukoencephalopathy 
(PML) is a neurological infectious disease 
caused by the John Cunningham polyomavirus 
(JCV),1,2 an opportunistic agent with world-
wide distribution. JCV is known to be indolent 
virus with very low viral replication rate in the 
vast majority of the hosts. In immunosuppres-
sion states, the virus can become reactivated 
which leads to olygodentrocytes destruction 
and demyelination.3 PML is frequently seen in 
patients with acquired immune deficiency syn-
drome (AIDS), lymphoproliferative diseases, 
stem cell transplantation, in patients receiving 
monoclonal antibodies as treatment4 and also 
in rheumatologic disorders. PML rarely occurs 
during the immunosuppressive treatment of 
systemic lupus erythematosus (SLE).5 The au-
thors describe a rare case of PML secondary to 
SLE treatment with an unusual location.
CASE REPORT
A 52-year-old female was admitted to our hos-
pital with progressive history of nausea, vom-
iting and recent gait instability. Past medical 
history was significant for SLE for more than 
25 years. The patient had cardiac and skin SLE 
involvement, receiving 400 mg of hydroxy-
chloroquine daily and mycophenolate mofetil 
500 mg daily for SLE treatment. She was ad-
mitted the same day. On exam she presented 
spontaneous nystagmus, transient diplopia, 
right arm dysmetria, ataxia, uncoordinated 
walking and gait ataxia. Additionally, she also pre-
sented reduced control of range of movement of 
the arms, moderate hypotonia and mild tremor.
The laboratory investigation demonstrated 
inactive SLE status. She had negative screen for 
human immunodeficiency virus (HIV), VDRL, 
aspergillosis and hepatitis B. The cerebrospinal 
fluid (CSF) analysis was normal for cell count, 
protein and glucose. The work-up for coagu-
lopathy was negative. The levels of vitamin B12 
and folate levels were within normal limits.
The computed tomography (CT) scan has 
shown an area of hypodensity in the left mid-
dle cerebellar peduncle, also involving the left 
side of the pons and the deep white matter of 
the left cerebellar hemisphere (Figure 1). Mag-
netic resonance imaging was subsequently 
performed and revealed isolated lesions in the 
posterior fossa. The lesion in the right cerebel-
lar peduncle extending to the right cerebellar 
hemisphere was hypo on the T1WI and hyper-
intense on the T2W/FLAIR images (Figures 2 
and 3). No mass effect or significant enhance-
ment were noted. The diffusion weighted im-
ages (DWI) revealed a slight peripheral rim of 
restricted diffusion (Figure 4). Este é um artigo Open Access sob
 a licença de CC BY-NC-ND
610
Figure 1: Plain CT of the brain in the axial plane demonstrates 
an isolated hypodense lesion in the left middle cerebellar 
peduncle extending anteriorly to involve the left side of 
the pons and posteriorly the deep white matter of the left 
cerebellar hemisphere.
Figure 2: Coronal T2WI demonstrates the demyelinating 
lesion in the deep portions of the right cerebellar hemisphere 
involving the subcortical white matter and also encompassing 
the dentate nucleus.
Figure 3: Note the extensive white matter signal changes 
in the pons, right cerebellar peduncle and hemisphere with 
dismal mass effect, a typical feature of PML.
Figure 4: Axial DWI image at the level of the posterior fossa 
demonstrating a curvilinear hyperintensity located at the 
margins of the demyelinating lesion. DWI hyperintensities in 
PML are associated with disease activity.
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Vasculitic changes secondary to SLE was on top on 
our differential diagnosis list in such clinical scenario, 
followed by PML. All the vasculitis work-up was nega-
tive, including a normal conventional cerebral angio-
gram. CSF analysis was repeated, this time to perform a 
JCV CSF polymerase chain reaction (PCR), since biopsy 
of the brain was precluded. The PCR testing for JCV was 
positive and the patient subsequently started on cidofovir. 
At the fourteenth day of admission, the patient became 
severely dysphagic and dysarthric. She also had acute pul-
monary embolism and aspiration pneumonia. After seven 
days, the patient passed away of pulmonary insufficiency. 
DISCUSSION
PML is a rare, subacute, progressive and usually fatal dis-
ease of the central nervous system (CNS). The disease is 
characterized by widespread demyelinating lesions due 
oligodendrocytes infection by the JCV. The main histo-
pathologic features of PML are: demyelination, enlarged 
nuclei of oligodendrocytes, and bizarre astrocytes.6 It has 
been suggested that more than 90% of the general popula-
tion present antibodies to the virus but less than 10% will 
show any evidence of viral replication. Isolation of the JCV 
in brain tissue confirms the diagnosis of PML. JCV CSF 
PCR has also been proved useful in the diagnosis of PML.6,7 
Typically the patients with PML present with cognitive 
impairment, altered mental status, aphasia, focal motor 
deficits, cortical blindness and behavioral changes.8,9
PML is predominately seen in cases of impaired cell-
mediated immune response, almost exclusively in patients 
with AIDS.8 Around 5% of these patients will develop PML, 
particularly when the CD4 counts are in the range of 50-100 
cells. Prior to the AIDS epidemic, PML was rarely seen in 
other immunocompromised patients occurring usually as 
a terminal event such as in cases of leukemia, lymphoma, 
systemic lupus erythematosus (SLE), Wiskott-Aldrich syn-
drome, and severe combined immunodeficiency (SCID).8,10 
In a recent study, Calabrese et al.5 reviewed 36 cases of PML 
associated with rheumatic disease. Each patient had been 
treated with various immunosuppressants before PML deve-
loped. Of all rheumatic conditions, such as rheumatoid arthri-
tis, Wegener granulomatosis, dermatomyositis, polymyositis, 
and scleroderma, SLE was most commonly associated with 
PML (23/35 cases). The average age of those with SLE was 
43 years and non-SLE was 50 years with females accounting 
for 19 of 23 cases. The presentation of PML was typical, with 
progressive neurologic deterioration occurring. 
Radiographic evidence of PML strongly supports its di-
agnosis, with MRI being the imaging modality of choice. 
PML lesions may occur anywhere, most frequently seen at 
the grey-white matter interface, involving the subcortical 
U fibers of the parieto-occipital regions and frontal lobes. 
These lesions are initially multiple and discrete, but may 
eventually coalesce into larger lesions. They most often 
are bilateral and asymmetric and rarely solitary.9,10 Lesions 
confined to the posterior fossa are uncommon.11
CT scans usually demonstrate bilateral asymmetric 
hypodense foci without mass effect or enhancement. On 
MRI these lesions appear hyperintense in the T2WI, typi-
cally involving the subcortical and also the periventricular 
white matter. When in the subcortical white matter, fluid-
attenuated inversion recovery (FLAIR) images are sensitive 
to demonstrate the demyelinating lesions, which appear hy-
perintense against a background of suppressed CSF signal 
intensity. Lesions appear hypointense and well demarcated 
on T1WI, although they may be isointense in the initial 
phase of the disease. Typically, PML lesions do not enhance, 
but faint peripheral enhancement has been described.12,13
It has been suggested that the appearance of DWI cor-
relates with the stage of the disease and may be useful for 
documenting response of PML.9 In active lesions a central 
core of facilitated diffusion often exists with a rim of dif-
fusion restriction at the advancing edge which is typically 
incomplete.14 Apparent diffusion coefficient (ADC) values 
have been reported to be much higher in the center of a 
lesion than at its periphery.15,16 This radiologic appearance 
has been correlated with large oligodendocytes, enlarged 
“bizarre astrocytes” with several large processes, and infil-
tration of foamy macrophages.6,17 Diffusion restriction at 
the margin is due to either reduced extracellular space or 
enlarged cells, as the water is trapped in the intracellular 
space.18-20 In older lesions, facilitated diffusion predomi-
nates. This is thought to be associated with disorganized 
cellular architecture, dead oligodendrocytes, which there-
by increases extracellular space, macrophage action, and 
astrocytic repair responses.14 
To date, there has been no specific treatment for PML. 
Several pharmacologic agents, such as cytarabine, cido-
fovir, and topotecan have been used in clinical trials to 
target JCV in the past. All studies did not show a clini-
cal benefit which outweighed the risk of potential toxicity 
related to those drugs.6 Discontinuation of immunosup-
pressant treatment has also traditionally been a treatment 
of choice.21 
REFERENCES
1.  Padgett BL, Walker DL, ZuRhein GM, et al. Cultivation of pa-
pova-like virus from human brain with progressive multifocal 
leucoencephalopathy. Lancet. 1971; 1(7712):1257-60.
2.  Padgett BL, Walker DL. Prevalence of antibodies in human 
sera against JC virus, an isolate from a case of progressive mul-
tifocal leukoencephalopathy. J Infect Dis. 1973; 127(4): 467-70.
3.  Schmidt H, Raasch J, Merkler D, et al. Type I interferon re-
ceptor signalling is induced during demyelination while its 
function for myelin damage and repair is redundant. Exp 
Neurol. 2009; 216(2):306-11.
612
4.  Weissert R. Progressive multifocal leukoencephalopathy. 
J Neuroimmunol. 2011; 231(1-2):73-77.
5.  Calabrese LH, Molloy ES, Huang D, et al. M. Progressive mul-
tifocal leukoencephalopathy in rheumatic diseases: evolving 
clinical and pathologic patterns of disease. Arthritis Rheum. 
2007; 56(7):2116-28.
6.  Cinque P, Koralnik IJ, Gerevini S, et al. Progressive multifocal 
leukoencephalopathy in HIV-1 infection. Lancet Infect Dis. 
2009; 9(10):625-36.
7.  D’Arminio Monforte A, Cinque P, Vago L, et al. A comparison 
of brain biopsy and CSF-PCR in the diagnosis of CNS lesions 
in AIDS patients. J Neurol. 1997; 244(1):35-9.
8.  Garrels K, Kucharczyk W, Wortzman G, et al. Progressive 
multifocal leukoencephalopathy: clinical and MR response to 
treatment. AJNR Am J Neuroradiol. 1996; 17(3):597-600.
9.  Smith AB, Smirniotopoulos JG, Rushing EJ. From the archives 
of the AFIP: central nervous system infections associated with 
human immunodeficiency virus infection: radiologic-patho-
logic correlation. Radiographics. 2008; 28(7):2033-58.
10.  Warnatz K, Peter HH, Schumacher M, et al. Infectious CNS 
disease as a differential diagnosis in systemic rheumatic dis-
eases: three case reports and a review of the literature. Ann 
Rheum Dis. 2003; 62(1):50-7.
11.  White RP, Abraham S, Singhal S, et al. Progressive multifocal 
leucoencephalopathy isolated to the posterior fossa in a pa-
tient with systemic lupus erythematosus. Rheumatology (Ox-
ford). 2002; 41(7):826-7.
12.  Shah R, Bag AK, Chapman PR, et al. Imaging manifestations 
of progressive multifocal leukoencephalopathy. Clin Radiol. 
2010; 65(6):431-9.
13.  Magalhaes Z, Reis AM, Moniz P, et al. Progressive multifocal 
leukoencephalopathy. Role of imaging in its diagnosis. Per-
spectives. Acta Med Port. 2001; 14(1):117-21.
14.  Bergui M, Bradac GB, Oguz KK, et al. Progressive multifocal 
leukoencephalopathy: diffusion-weighted imaging and patho-
logical correlations. Neuroradiology. 2004; 46(1): 22-5.
15.  Collazos J, Mayo J, Martinez E, et al. Contrast-enhancing pro-
gressive multifocal leukoencephalopathy as an immune recon-
stitution event in AIDS patients. AIDS. 1999; 13(11):1426-8.
16.  Ohta K, Obara K, Sakauchi M, et al. Lesion extension de-
tected by diffusion-weighted magnetic resonance imaging in 
progressive multifocal leukoencephalopathy. J Neurol. 2001; 
248(9):809-11.
17.  Whiteman ML, Post MJ, Berger JR, et al. Progressive multifo-
cal leukoencephalopathy in 47 HIV-seropositive patients: neu-
roimaging with clinical and pathologic correlation. Radiology. 
1993; 187(1):233-40.
18.  Norris DG, Niendorf T, Hoehn-Berlage M, et al. Incidence of 
apparent restricted diffusion in three different models of cer-
ebral infarction. Magn Reson Imaging. 1994; 12(8):1175-82.
19.  Verheul HB, Balazs R, Berkelbach van der Sprenkel JW, et al. 
Comparison of diffusion-weighted MRI with changes in cell 
volume in a rat model of brain injury. NMR Biomed. 1994; 
7(1-2):96-100.
20.  Qiao M, Malisza KL, Del Bigio MR, et al. Transient hypoxia-
ischemia in rats: changes in diffusion-sensitive MR imaging 
findings, extracellular space, and Na+-K+-adenosine triphos-
phatase and cytochrome oxidase activity. Radiology. 2002; 
223(1):65-75.
21.  Koralnik IJ. Progressive multifocal leukoencephalopathy re-
visited: Has the disease outgrown its name? Ann Neurol. 2006; 
60(2):162-73.
Progressive multifocal leukoencephalopathy restricted to the posterior fossa
